[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

November 2016 | 80 pages | ID: C46CBA6264EEN
La Merie Publishing

US$ 784.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as
  • Combination therapies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and
  • Chimeric Antigen Receptor (CAR) T-Cells.
This report describes the profiles of 16 different specific and bispecifi anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecules has been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented. This report describes and analyzes the
  • Target Background & Scientific Rationale
  • Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD22 Immunotherapeutics
  • Profiles of Companies with CD22-Targeted Immunotherapeutics.
Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
Naked antibodies;
Radioimmunotherapy (RIT);
Immunotoxins (IT);
Antibody-Dug Conjugates (ADC); and
Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics.
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics



More Publications